Immune checkpoint inhibitors (ICIs) in immunotherapy, restore the killing ability of immune cells to tumors by inhibiting the molecular interactions such as PD-1 and PD-L1 on the surface of tumor cells or immunosuppressive cells, then recognize the antigens of tumors and kill the tumor cells subsequently (Couzin-Frankel, 2013). Here, CD274 is linked to neoplasm.